Gene-editing is of enormous significance in the prevention and treatment of human disease. But caution is not a bad thing. Original Link
It takes surprisingly long to fill a plastic tube with spit. Finally, I’m ready to put the lid on the tube and slide it into an envelope that comes with the test kit.
It’s my first personal DNA test, and I’m doing it with Singapore startup Imagene Labs.
Once the startup has analyzed my genetic code – it takes two to three weeks – I will receive personalized wellness recommendations: What foods to avoid, what products are good for my skin, and how I should exercise.
“Precision wellness” is how Imagene Labs director Jia Yi Har describes her work.
Personal DNA tests became popular in the US with companies like 23andMe and Ancestry.com, who tell you about your genetic heritage. The results are mostly fun discoveries – perhaps you have an unexpected strand of Native American ancestry in your family tree.
Imagene Labs takes it further. Its main product, Ori, is a DNA testing platform and subscription business in one. Once Ori knows the genetic properties of your skin, digestive tract, and muscle tissue, it concocts tailor-made products that you can have shipped to your home.
The skin serum comes in a slender white bottle with your name on it. This stuff is made to perfectly balance your skin type.
Then there’s a food supplement, a mixture of granules in different shades of green. It contains nutrients and vitamins which your body tends to lack due to genetic predispositions, all in the right percentage.
“The exercise you have to do yourself,” says Reza Harith, who joined Imagene’s team after working as a brand manager at a fitness studio chain.
The Ori results come with exercise recommendations, put together by fitness experts based on what your DNA says about your muscle growth capacity, metabolism, and other factors.
Creating DNA-based products and services became possible because the cost of DNA sequencing has gone down, Har explains.
The Human Genome Project, the first effort to fully identify and map human DNA, was completed in 2003 after more than a decade of research that cost billions of dollars. “It only costs about US$1,000 and takes considerably less time now,” says Har. “Everything about the process, the sequencing itself, the chemicals used, the processing power required, all of this has improved, resulting in the price drop.”
Another key innovation startups like Imagene Labs rely on is Illumina. The process allows researchers to isolate specific locations in the genetic code. These are called SNPS – pronounced snips.
“We know which particular locations are proven to contribute to the traits we are interested in,” Har says. Imagene includes only those snips in its analysis that have “thousands of published scientific studies” backing up their correlation with certain traits.
To make that more concrete: One of the genes tested in Ori’s fitness analysis is called IGF2. It’s proven to be associated with muscle soreness. My particular variation of this gene puts me into “90th percentile” of the average population – in other words, I have a higher than average likelihood of feeling sore after exercise.
With Illumina, Imagene can focus on pre-selected snips. This doesn’t only make it faster, it also helps avoid ethical and legal complications – if a startup had your full genome, it could potentially also know about critical diseases.
Using DNA for medical diagnostics is its own discipline with a slew of regulations, explains Har.
Imagene’s parent company, Asia Genomics, is in this business. It runs medical diagnostics like prenatal tests, which look for abnormalities in babies before they are born. They are distributed through clinics and administered by professionals. Everything needs to be certified.
Focusing on wellness means Imagene Labs isn’t bound by the same requirements. Its association with Asia Genomics gives it a huge leg up because it can share the parent firm’s professional lab facilities and team resources.
Asia Genomics has so far raised US$12 million from investors like Formation 8, Raffles Venture Partners, Spring Seeds, and some angel investors, Har says.
Asia Genomics started in 2014, and Imagine Labs spun out in 2016 as an attempt to spark consumer interest in DNA-based personalization.
Ori was first available in Singapore, then in Malaysia, Thailand, Hong Kong, and Jakarta. There’s also a second full lab in Beijing.
Asia is a good place to start with these products because people are generally willing to experiment when it comes to wellness and beauty, Harith says. He is establishing relationships with spas and fitness centers as distribution channels for Ori.
“Intravenous vitamin drips, chemical peels, and fillers – in Thailand and Malaysia, it’s common to try these,” he says. While Singaporeans tend to be more skeptical about new trends, they do often get on board later once fringe trends trickle into the country from its neighbors.
Even though DNA sequencing prices have gone down, Ori is still an investment many will think about twice. Just one of the tests, the skin test, costs US$184. This comes with a 30-day supply of your personalized facial serum. After it’s done, you can get a new bottle for US$89.
The number of tests run since Ori’s launch in 2016 is “in the thousands,” Har says. There’s not been a clinical trial on the effectiveness of recommendations and products provided, but client feedback, she adds, has been encouraging.
Imagene Labs is at the cutting edge of the DNA personalization trend. Only a few other startups, mostly US-based, are exploring the opportunities.
Science is not yet convinced that DNA-based fitness and wellness has massive benefits over regular practices.
An article by Vox quotes John Mathers, the director of the Human Nutrition Research Center at Newcastle University, on his interpretation of Habit’s product. His group had done research comparing different types of personalized dietary advice to a control group.
Those that received personalized advice did perform better, but “there was no evidence that including phenotypic and phenotypic plus genotypic information enhanced the effectiveness of the [personalized nutrition] advice,” Mathers said.
In other words, DNA-based personalization was not doing significantly better than other forms of personalized advice.
But with falling costs and fast-developing tech, Har believes it’s only a matter of time until there are products that make the jump from the fringe to the mainstream.
“There’s no going back,” she says. “Precision medicine has started. President Obama set up an initiative in the US to sequence the population, looking for insights that help lower healthcare costs. Other countries are following suit.”
That’s the medical side, she points out. “The wellness market is actually three times larger than the medical market.”
Consumers in Asia spend massive amounts on beauty products. Ori’s skin serum is so far its best-selling product.
The Asia-Pacific beauty and healthcare market amounted to US$98.5 billion in 2015 and will grow to around US$127 billion by 2020, according to Statista. Globally, Asia Pacific makes up the largest share of the market.
The cosmetics industry is in constant need to innovate, Har says. This has led to an immense variety of ingredients, design, and marketing messages. And according to Har, beauty brands have been watching Imagene Lab’s work with great interest.
As for my Ori test results, I found many interesting recommendations that often matched what I already knew about myself. The most helpful advice, perhaps, was in the nutrition analysis, which found a high genetic predisposition for COQ10 deficiency – a coenzyme that provides energy to cells for growth and maintenance. Instead of buying Ori’s own supplement mix, I chose to get my own and follow the dietary recommendations. Which in my case, means adding plenty of liver and kidney to my diet. Yum.
Converted from Singapore dollar. Rate: US$1 = S$1.35.
A new biotech-focused accelerator program launched by Singaporean VC firm Vertex Ventures and Temasek Life Sciences Laboratory (TLL) kicked into gear this week with the confirmation of several key executives.
Temasek Life Sciences Accelerator (TLA) will focus on spinning out inventions and growing startups in three key areas – agri-food technology, industrial and synthetic biology, and human and veterinary sciences. It aims to become the “go-to incubator for life sciences in Singapore.”
TLA says it launched last year, though little has been heard about it up until today when it announced key executive appointments.
Han Sang-Uh – previously a director at Vertex – has been appointed managing director of TLA. In this post, Han oversees the commercialization and spin-off of technologies developed at TLL – a research institution supported by Temasek Trust, the philanthropic arm of Singaporean sovereign fund and Vertex parent Temasek Holdings, and affiliated with the National University of Singapore and Nanyang Technological University. He also manages investment activity relating to startups from outside of the lab. Han’s LinkedIn profile indicates that he has been in the role since April this year.
TLA also announced the appointment of Peter Chia, CEO at both TLA and TLL, and investment and risk management consultant Judy Lee as members of its board of directors.
Other board members include TLA chairman Teo Ming Kian, Vertex CEO Chua Kee Lock, and Anuj Maheshwari, managing director at Temasek Holdings.
Those interested in pitching their business plans can contact TLA here.
Sign up for an account and get the latest & best stories in your inbox, every day.